People news: JAMA, King Pharmaceuticals

Share this article:

Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. But she was also criticized for letting some author conflicts go undisclosed. Formerly a vice dean at the Johns Hopkins University School of Medicine, DeAngelis plans to return to the school to develop a Center for Professionalism in Medicine and the Related Professions. A search is on for her replacement, and a successor will be named by next July, the journal said. According to Kantar Media's Journal Ad Review, JAMA ranked second among medical/surgical publications by 2009 ad revenue, while ad pages fell 12.8% vs. 2008.

King Pharmaceuticals named Jeffrey Bailey chief commercial officer. Bailey joins the company from Novartis, where he was a general manager. He will be responsible for all commercial activities in branded pharma and will lead sales, marketing, managed care, sales operations and business analytics.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.